2030 Dosage Pharmaceutical Companies 
European Pharmaceutical Review
OCTOBER 7, 2022
A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc.,
European Pharmaceutical Review
FEBRUARY 3, 2023
Positively, it comes at a time when securing fill finish capacity can be a challenge for many pharmaceutical companies. The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance. HPAPI contract manufacturing to value $14.6
Expert insights. Personalized for you.
98 
Let's personalize your content